Q-omics provides the consensus-scored CYCSP23 profile across patient tissues and cancer cell-line models. CYCSP23 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CYCSP23 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, CYCSP23 RNA expression shows 13,572 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, and LSCC as cancer lineages where CYCSP23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP23 survival associations across molecular data types. CYCSP23 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP23 RNA expression–survival associations across cancer types. High CYCSP23 expression shows unfavorable associations in BRCA, SKCM, ACC, MESO, UCEC and GBM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for CYCSP23 RNA expression.
This table summarizes CYCSP23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP23 shows lower tumor expression in BRCA and LUSC and higher tumor expression in KIRC. The BRCA box plot shows higher CYCSP23 RNA expression in normal versus tumor tissue (log2 FC = −0.111, t-test p = .005).
This table shows molecular features associated with CYCSP23 in patient tissues and cancer cell lines. In patient samples, CYCSP23 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
